Blackstone Delays Auction for CMAX Clinical Trials Amid ACCC Divestment Order

While attention has been focused on TPG Capital's attempts to exit its $4 billion investment in Novotech, a smaller but significant deal involving clinical trials has emerged. Blackstone, a global investment firm, is currently managing the divestment of Adelaide's CMAX Clinical Research. This move is a direct result of a condition set by the Australian Competition and Consumer Commission (ACCC) to approve Blackstone's acquisition of Tokyo-listed I'rom Group. CMAX Clinical Research, known for its 78 patient beds dedicated to phase one clinical trials, serves global biotech and pharmaceutical companies. The divestment is part of Blackstone's strategy to integrate I'rom Group into its Nucleus Network, which was acquired from Crescent Capital for approximately $600 million in 2021. Mid-market private equity firms are reportedly preparing to bid for CMAX, highlighting the ongoing interest and investment in the clinical trials sector.